

| | | | | | |
|---|---|----|---|--------------------------|----------------------------|
| Subst. for form 1449/PTO | | | | Complete if Known | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/735,863 |
| | | | | Filing Date | December 15, 2003 |
| | | | | First Named Inventor | Lee R. Brettman |
| | | | | Art Unit | 1644 |
| | | | | Examiner Name | Ronald B. Schwadron, Ph.D. |
| Sheet | 1 | of | 9 | Docket Number | 079259-0237 |

| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
|---|----------|---|------------|-----------------|--|
| EXAMINER'S INITIALS | CITE NO. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| /R.S./ | AZ5 | Fedyk, et al., "Regional Immunomodulation of the gastroIntestinal tract without systemic Immunosuppression in Cynomolgus macaques by vedolizumab," 15(S2): S50, Abstract P-0144, <i>Inflammatory Bowel Diseases</i> , (2009). | | | |
| /R.S./ | AR6 | Feagan, et al., "Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD," 15(S2): S12, Abstract P-0025, <i>Inflammatory Bowel Diseases</i> , (2009). | | | |
| EXAMINER <i>/Ronald Schwadron/</i> | | | 09/27/2010 | DATE CONSIDERED | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.